SUMMARY
Women with inherited mutations in the BRCA1 gene have increased risk of developing breast cancer but also exhibit a predisposition for the development of aggressive basal-like breast tumors. We report here that breast epithelial cells derived from patients harboring deleterious mutations in BRCA1 (BRCA1 mut/+ ) give rise to tumors with increased basal differentiation relative to cells from BRCA1 +/+ patients. Molecular analysis of disease-free breast tissues from BRCA1 mut/+ patients revealed defects in progenitor cell lineage commitment even before cancer incidence. Moreover, we discovered that the transcriptional repressor Slug is an important functional suppressor of human breast progenitor cell lineage commitment and differentiation and that it is aberrantly expressed in BRCA1 mut/+ tissues. Slug expression is necessary for increased basal-like phenotypes prior to and after neoplastic transformation. These findings demonstrate that the genetic background of patient populations, in addition to affecting incidence rates, significantly impacts progenitor cell fate commitment and, therefore, tumor phenotype.
INTRODUCTION
Tumor suppressor genes, such as BRCA1, repress malignant transformation by ensuring the fidelity of DNA replication and chromosomal segregation in response to potentially deleterious events. The increased risk of breast cancer development in individuals with inherited mutations in BRCA1 has been attributed to compromised DNA damage repair activity (Welcsh and King, 2001 ). However, it has been unclear why mutations in BRCA1 are also preferentially associated with an increased propensity for developing a specific subtype of breast cancers, basal-like tumors, with a distinct molecular phenotype and a poor prognosis Arnes et al., 2005) . Recent evidence has indicated that BRCA1 might function to regulate mammary epithelial cell morphogenesis and differentiation (Furuta et al., 2005; Liu et al., 2008; Kubista et al., 2002) . Whether these functions of BRCA1 directly relate to the increased development of basal-like breast cancer, however, is not known.
Human breast tissue contains two major specialized epithelial cell types: luminal cells with secretory functions surrounding the inner breast duct lumen and basal/myoepithelial cells with contractile functions that interface between luminal cells and the basement membrane. Corresponding to these cell states, human breast cancers are broadly classified into luminal-like or basal-like tumors based on their gene expression patterns (Peppercorn et al., 2008) . Accordingly, it has been proposed that tumors with ''luminal'' characteristics may result from the transformation of cells within the luminal lineage, whereas tumors exhibiting ''basal-like'' differentiation may arise from basal cells. However, there is also a wealth of evidence indicating that breast tumors exhibiting luminal or basal-like differentiation have distinct constellations of genetic aberrations, which may also influence tumor phenotype. For example, luminal tumors frequently express elevated levels of cyclin D1 (CCND1) and sustain mutations in phosphoinositide 3-kinase (PI3K) (Gauthier et al., 2007; Loi et al., 2009; Saal et al., 2005; Campbell et al., 2004) , whereas dysregulated expression of ras isoforms, mutations in p53, loss of PTEN expression, and loss or silencing of BRCA1 are more commonly associated with basal-like tumors (Gluz et al., 2009; Rakha et al., 2008; Miyakis et al., 1998) . Moreover, as mentioned above, inherited mutations in BRCA1 (BRCA1 mut/+ ) strongly predispose for the formation of basal-like tumors (Foulkes, 2003; Foulkes et al., 2004; Arnes et al., 2005) . In principle, the predisposition for basal-like tumors in BRCA1-mutation carriers could result either from the differentiation state of the precursor cells or from the genetic alterations acquired during tumor formation. In this study, we examined the biology of disease-free breast tissues from patients harboring deleterious mutations in BRCA1. In doing so, we found a relationship between genetic alterations in perturbing mammary progenitor differentiation and their influence on tumor phenotype.
RESULTS

Creation of Human Breast Cancers In Vivo Exhibiting Heterogeneous Differentiation
To examine the connection between the role of BRCA1 in breast progenitor cell differentiation with the susceptibility of BRCA1-mutation carriers to developing basal-like breast cancers, we used a recently described method for creating human breast tissues in vivo (Proia and Kuperwasser, 2006; Wu et al., 2009 ). This method involves three distinct temporal steps: (1) clearing of the murine mammary fat pad, (2) reconstitution of the mammary fat pad with human stromal cells, and (3) introduction of lentiviral-infected organoids comixed with activated fibroblasts into the humanized fat pad. Because this system does not require any cell culture, the likelihood of genetic alterations or the selection of variant phenotypes during in vitro expansion is minimized.
In an attempt to generate tumors from patient-derived breast epithelial cells, we modified step (3) above by introducing oncogenes into dissociated single cell suspensions of epithelial cells before introducing them into humanized stroma ( Figure 1A ). We chose a set of oncogenes reflective of both the luminal and basal tumor classes to reduce the potential for genetic bias toward either tumor subtype. We infected uncultured breast epithelial cell suspensions obtained from dissociated reduction mammoplasty tissues with lentiviruses harboring genes for a mutated form of p53 (p53R175H), wild-type cyclin D1 (CCND1), a constitutively activated form of P13K (PI3KCA), and an oncogenic form of K-ras (RasG12V). Breast tumors developed when all four genes were introduced simultaneously into the breast epithelial cells (Figures 1B and 1C) .
Tumor formation with this procedure was observed with reduction mammoplasty tissues obtained from multiple patient samples. Expression of the introduced genes in the generated breast tumors was verified by immunostaining (for p53, cyclin D1, and p-Akt) and RT-PCR (for K-ras) ( Figure 1D ). Hematoxylin and eosin (H&E) stains of tumor sections revealed that the tumors were heterogeneous invasive carcinomas with regions of mixed squamous and papillary features ( Figure 1E ; Figure S1 available online). Immunostaining showed that cancer cells in squamous metaplastic regions expressed markers indicative of basal differentiation (cytokeratin 14 [CK14], p63, and vimentin [VIM] ) and those within papillary regions expressed luminal markers (estrogen receptor [ER] , CK8/18, and CK19) ( Figure 1E) .
We next applied this transformation protocol to mammary epithelial cells obtained from prophylactic mastectomy tissues from patients harboring deleterious mutations in BRCA1 (BRCA1 mut/+ ) (Table S1, Figure S1 ). We observed that the identical set of oncogenes was sufficient to transform epithelial cells obtained from BRCA1 mut/+ patients ( Figure 2A ). Although the introduced oncogenes were expressed to the same extent in wild-type and BRCA1 tumor tissues, immunostaining of tissue sections revealed strong expression of the basal epithelial markers CK14, p63, and vimentin in BRCA1 mut/+ tumor cells (Figures 2B and 2C) . In addition, although tumors arising from BRCA1 +/+ epithelium exhibited regions that were CK8/18 and ER positive, tumors arising from BRCA1 mut/+ cells showed a statistically significant reduction in both CK8/18 and ER expression and increased CK14 expression, which is typical of basal-like tumors ( Figure 2C ). To evaluate more comprehensively whether the tumors generated from BRCA1 mut/+ epithelium exhibited increased basal-like features, we performed global gene expression analyses (Table  S2 ). Hierarchical clustering indicated that tumors arising from either BRCA1 +/+ or BRCA1 mut/+ epithelium could be segregated from one another based on global transcriptional profiles (Figure 2D) . Gene set enrichment analysis (GSEA) revealed that BRCA1 mut/+ tumors exhibited a significant upregulation of genes associated with breast epithelial basal/myoepithelial cell differentiation compared to the tumors arising from BRCA1
+/+ cells ( Figure 2E : basal gene set I, p < 0.024; basal gene set II, p < 10 À4 ; Table S3 ). In addition, GSEA indicated specific upregulation of genes in the human breast cancer ''basal-like'' centroid, which identifies the human basal-like tumor phenotype (Hu et al., 2006) in BRCA1 mut/+ tumors (basal centroid, Figure 2E , p < 0.033; Figure S2 ). However, gene-expression profiling indicated that many genes were differentially expressed between BRCA1 +/+ and BRCA1 mut/+ epithelial cells ( Figure 3A ; Table S4 ; Figure S2 ). Examination of gene ontology functional processes indicated that a number of genes associated with DNA transcription (repressor and activator), DNA binding, establishment and/or maintenance of chromatin architecture, and chromatin assembly or disassembly were differentially expressed in BRCA1 mut/+ epithelium relative to BRCA1 +/+ epithelium ( Figure 3B ). Examination of genes associated with epithelial differentiation revealed that luminal genes and various hormone-related genes including progesterone and estrogen beta receptors (PGR, ESR2) (Table S4) were downregulated in BRCA1 mut/ + cells, while genes associated with progenitor or basal cells were upregulated ( Figure 3A ; Table S4 ). We confirmed these differences in differentiation by using semiquantitative immunohistochemistry (Allred scoring metric, see Experimental Procedures) applied to disease-free prophylactic mastectomy tissues obtained from BRCA1 mut/+ carriers and age-matched reduction mammoplasty tissues from BRCA1 +/+ noncarriers.
Consistent with the microarray results, progesterone receptor (PGR) expression was significantly reduced in luminal epithelial cells in 88% of BRCA1 mut/+ tissues compared to only 11% of BRCA1 +/+ breast tissues (Allred score > 5, p < 0.001) ( Figure 3C ; Table S5 ). In addition, trefoil factor 3 (TFF3), which is also Figure 3C ; Table   S5 ). In contrast, 88% of BRCA1 mut/+ tissue samples exhibited moderate-to-high expression of the basal marker vimentin compared to 16% of BRCA1 +/+ tissues ( Figure 3C ; Table S5 ; p < 0.086).
We next used flow cytometry to assess the proportion of lineage-committed and progenitor epithelial cells in breast tissues. Cells expressing CD24 or high levels of EpCAM (ESA) enrich for cells of the luminal lineage, whereas cells expressing high levels of CD49f enrich for cells of the myoepithelial (ME)/ basal lineage (Villadsen et al., 2007; Shipitsin et al., 2007 Figure 3D ; Figure S2; Keller et al., 2010; Lim et al., 2009; Eirew et al., 2008) .
Analysis of prophylactic mastectomy tissues from BRCA1 mut/+ (<50 year) tissues also identified four populations of epithelial cells but revealed a statistically significant increase in the proportion of EpCAM À /CD49f + basal progenitor cells (p < 0.04; Figure 3D ) and an appreciable but not statistically significant decrease in the number of EpCAM hi /CD49f + luminal progenitor cells. These results indicate that BRCA1 mut/+ tissues exhibit luminal and basal epithelial cell differentiation defects prior to any evidence of cancer.
Characterization of Progenitor Cells from BRCA1-Mutation Carriers
We next evaluated progenitor activity of mammary epithelial cells obtained directly from breast tissues. We employed mammosphere (Dontu et al., 2003) and adherent colony-formation (Stingl et al., 2001) assays to assess breast progenitor activity, and we evaluated whether they arose from luminal-committed, basal/ME-committed, or bipotent progenitors by staining for the differentiation markers CK14 and CK8/18. We found no significant differences in the formation of primary mammospheres, suggesting that the total number of stem/progenitor cells may not differ between BRCA1 +/+ and BRCA1 mut/+ tissues ( Figure S3 ). In addition, there was no significant difference in the distribution of CK8/18 + and CK14 + cells within both BRCA1
and BRCA1 mut/+ mammospheres ( Figure S3 ).
Under adherent conditions, we found that human breast epithelial cells generated spherical colonies that grew in suspension as well as adherent colonies that grew on plastic ( Figure 3E ; Figures S3). Although we did not observe a statistically significant difference in the number of adherent progenitor colonies arising from BRCA1 mut/+ cells, we did observe that spherical luminal colonies derived from BRCA1 mut/+ cells expressed significantly higher levels of the basal maker CK14 in comparison to colonies from BRCA1 +/+ cells that were more uniformly CK8/ 18 positive ( Figure 3E ). We also assessed the in vivo outgrowth competency of progenitor cells from BRCA1 mut/+ and BRCA1 +/+ cells. By using the humanized cleared fat pad system, we found that BRCA1 +/+ cells generated mature bilayered ductal/acinar outgrowths, which contained an inner luminal layer of epithelial cells that stained predominantly for CK8/18 and 19, and an outer myoepithelial layer that stained for the basal/ME marker CK14 and SMA. In contrast, BRCA1 mut/+ cells gave rise primarily to immature ductal/acinar outgrowths that exhibited a significant increase in bipotent luminal cells that expressed both CK19 and CK14 and to a lesser degree CK8/18 and CK14 ( Figure 3F ; Figure S3 ). Taken together, these results reveal that luminal progenitor cells from BRCA1 mut/+ tissue exhibit defects in full maturation and differentiation and retain features of basal differentiation.
Luminal Cells Give Rise to Tumors in BRCA1-Mutation Carriers
We next wanted to determine whether the increased basal differentiation observed after neoplastic transformation of BRCA1 mut/+ cells was due to the increased numbers of EpCAM À basal cells or to the increased basal differentiation state of luminal progenitor cells. Accordingly, we enriched for either luminal (EpCAM + ) or basal/ME (CD10 + ) cells ( Figure 4A ) prior to lentiviral infection and injection into the mammary fat pad. Each subpopulation was isolated from breast tissues to >90% purity, as gauged by immunofluorescence ( Figure 4B ). The CD10 + subpopulation was enriched for basal/ME CK14 
Slug Suppresses Breast Progenitor Cell Lineage Commitment
To investigate the mechanism by which BRCA1 mutation affects progenitor cell differentiation, we classified the breast epithelial gene-expression signature described above based on signaling pathways that were differentially expressed in BRCA1 mut/+ cells.
Remarkably, the most significantly represented signaling pathways identified in BRCA1 mut/+ breast epithelial signature were the Wnt, Notch, and melanogenesis pathways ( Figure S4) . Notably, the transcriptional repressor Slug, which is an established regulator of melanocyte development, is a downstream target of both Wnt and Notch signaling (Niessen et al., 2008; DiMeo et al., 2009 ). This connection prompted us to examine Slug expression in breast epithelial tissues and cells harboring We did not find differences in SLUG mRNA expression, consistent with the microarray data, but we did observe abundant Slug protein in 87% of disease-free BRCA1 mut/+ prophylactic mastectomy tissues, while its expression was reduced in tissues from reduction mammoplasty BRCA1 +/+ tissues (Allred score > 1, p < 0.01) ( Figure 5A ).
Because Slug is a transcriptional repressor, we next investigated whether Slug expression might be affecting breast progenitor lineage commitment and differentiation. Because serum addition can promote cellular differentiation of immortalized human mammary epithelial cells (HMECs), which are a model for bipotent breast progenitor cells (Keller et al., 2010; Zhao et al., 2010) Figure 5C ).
To investigate whether Slug directly represses breast epithelial lineage commitment and differentiation, we used lentiviral-mediated short hairpin inhibition of Slug expression in primary prophylactic mastectomy cells isolated from three different patients with deleterious BRCA1 mutations. Slug knockdown led to a reduction in the proportion of EpCAM À /CD49f + progenitor cells and a concomitant increase in the proportion of EpCAM + , CD44 lo , and CD24 + luminal cells ( Figure 5D ; Figure S5 ).
Furthermore, expression of the basal marker vimentin was greatly reduced, while expression of the luminal marker CD24 was increased ( Figure 5C ; Figure S5 
BRCA1 Regulation of Slug Protein Stability
To examine whether BRCA1 regulates Slug expression, we used short interfering RNAs (siRNA) to inhibit BRCA1 expression in human breast MCF10A cells, which express wild-type BRCA1 (Elstrodt et al., 2006) . Quantitative RT-PCR and western blotting confirmed knockdown of transcript and BRCA1 protein expression ( Figure 6A ). Knockdown of BRCA1 by siRNA led to a modest but highly reproducible 2-fold increase in Slug protein expression, in the absence of increased mRNA expression ( Figure 6A ). These results suggest that loss of BRCA1 may lead to increased Slug protein expression by a posttranslational mechanism. We therefore examined the stability of Slug protein in cells after siRNA inhibition of BRCA1 as well as in cells with mutations in BRCA1. We confirmed that Slug protein was highly unstable in the BRCA1 +/+ MCF10A cells ( Figures 6B and 6C ). BRCA1 mut cells (SUM149, SUM1315) and siBRCA1-MCF10A cells were collected at regular time intervals subsequent to cyclohexamide (CHX) treatment and subjected to western blot analysis. Whereas Slug protein levels were turned over in siControl-MCF10A cells, Slug protein was still detected up to 6 hr after CHX treatment in siBRCA1-MCF10A cells and in cancer lines harboring mutations in BRCA1 ( Figure 6C ). Importantly, the difference in stability noted in Slug protein in BRCA1 mut SUM149 and SUM1315 cells was not due to a defect in proteasome activity, as indicated by the fact that cyclin D1 protein was still degraded. Taken together, these results indicate that BRCA1 regulates Slug protein stability. To begin to understand the mechanism involved, we looked at whether the ubiquitin ligase function of BRCA1 might be Figure S6 ). We next examined direct interactions between BRCA1 and Slug proteins. However, coimmunoprecipciaton of Slug with BRCA1 failed to demonstrate an interaction ( Figure S6 ), although we did observe interaction between BRCA1 and BARD1. Further studies will be needed to determine which BRCA1 functions are involved in regulating Slug protein stability.
Slug Regulation of Basal-like Breast Cancer Phenotype
To assess the role of Slug in basal-like breast cancer phenotype, we first examined its expression in sporadic and BRCA1-associated breast tumor tissues. Slug protein was preferentially expressed in ER-negative tumors derived from BRCA1-mutation carriers as well as ER-negative sporadic breast cancers, but its levels were higher in BRCA1-associated breast cancers (p < 0.007) ( Figure 7A ). Furthermore, Slug protein was expressed in cell lines derived from basal-like breast cancers and elevated in cancer cell lines that harbored mutations in BRCA1 ( Figure 7B ). To determine whether Slug is necessary for regulating the basal-like tumor phenotype, we used lentiviral-mediated short hairpin inhibition of Slug in breast cancer cells derived from primary patient BRCA1 mut breast cancers. We found that shSlug reduced endogenous Slug mRNA levels between 40% and 80% in BRCA1 mut SUM149 and SUM1315 cancer cell lines and reduced protein to nearly undetectable levels ( Figure 7C ). Slug inhibition resulted in a $6-fold reduction in the proportion of CD44 + /CD24 À stem-like basal cells in SUM149 and a $4-fold increase in the proportion of CD44 À /CD24 + luminal cells, consistent with increased luminal differentiation and reduced basal/ stem-like differentiation ( Figure 7C ). Similarly, reducing Slug expression in BRCA1 mut SUM1315 cells increased the proportion of CD24 + luminal cells by nearly 3-fold ( Figure S7 ). We also performed quantitative mRNA expression profiling by using a custom qRT-PCR array targeting 86 genes associated with basal/ME, luminal, or stem cell differentiation (Table S6) . Consistent with the changes observed by flow cytometry, inhibition of Slug resulted in upregulation of luminal genes in tumor cells including CK19, CK8, E-cadherin, MUC1, CD24, and TFF3, and repression of basal, mesenchymal, and stem cell genes in both SUM149 and SUM1315 lines ( Figure 7D ). To further demonstrate the role of Slug in the development of basal-like breast cancers in BRCA1 mut/+ cells, mammary Figure 7E) .
Finally, to demonstrate the connection between Slug expression and BRCA1 mutation before transformation, we examined whether the genes that were induced upon Slug inhibition were differentially expressed based on BRCA1 status in disease-free tissues (Slug Gene Set, Table S3 ). We used GSEA to evaluate the expression of these Slug transcriptional targets in BRCA1 mut/+ epithelium from four different patient samples. Six out of eight Slug target genes were repressed in BRCA1 mut/+ cells relative to BRCA1 +/+ cells ( Figure S7 ), yielding significant enrichment by GSEA (p < 0.0207). Collectively, these results show that upregulation of Slug inhibits luminal lineage commitment and increases the propensity for the formation of basal-like breast tumors.
DISCUSSION
A fundamental difference between breast cancers arising in BRCA1-mutation carriers compared to sporadic cancers is their tendency toward a basal subtype. By using an in vivo model that minimized cell culture, we were able to create human breast cancers that recapitulated many features of clinically relevant tumors to validate the previously untested idea that the predisposition for basal-like tumors in BRCA1-mutation carriers arises from perturbations in breast epithelial differentiation caused by compromised BRCA1 function (Foulkes, 2003) . Our results show that breast epithelial cells isolated from BRCA1-mutation carriers preferentially form tumors with increased basal differentiation compared to cells isolated from noncarrier tissues. In addition, we found that EpCAM + /CD10 -luminal cells from both BRCA1 +/+ and BRCA1 mut/+ tissues enriched for tumor-forming ability in this model system, but that the latter exhibited increased features of basal differentiation prior to transformation. However, since basal progenitor cells were also expanded in disease-free breast tissues from BRCA1 mut/+ tissues, it is possible that these cells might also serve as targets of neoplastic transformation in patients. Nevertheless, our findings are consistent with the notion that tumor phenotype can be significantly impacted by the pre-existing differentiation state of the normal precursor (''cell of origin'') targeted for neoplastic transformation (Gupta et al., 2005; Ince et al., 2007) . However, since mutations in a single allele of BRCA1 can alter the differentiation potential of the same cellular targets of transformation, leading to tumors with different phenotypes, this indicates that the initiating genetic mutation (''mutation of origin'') is a critical factor in defining tumor subtype. Future studies will be needed to determine whether other combinations of cooperating oncogenes give rise to BRCA1-associated basal-like tumors in basal/ME cells and whether mutations in other tumor-suppressor genes or oncogenes also affect the differentiation potential of progenitor cells that drive tumor phenotypes. Although we have not excluded the possibility that LOH of the wild-type BRCA1 allele is necessary for basal-like tumor formation, tumors in this model system were driven by ectopic oncogenes, suggesting that LOH was not necessarily a rate-limiting step. Furthermore, LOH is a stochastic event in BRCA1 mut/+ patients, affecting the mutant or wild-type alleles with similar frequencies (Clarke et al., 2006) . Because the analysis of prophylactic mastectomy tissues showed differentiation defects in significant proportions of the breast tissue, this suggests that LOH was probably not responsible for the perturbations in breast epithelial differentiation or basal tumor phenotype. Our findings, combined with those of others (Burga et al., 2009; Lim et al., 2009) indicate that haploinsufficiency of BRCA1 affects breast epithelial differentiation and progenitor cells in patients.
The present study also provides several additional lines of evidence that breast epithelial differentiation is altered in the presence of BRCA1 mutations. First, genes involved in epigenetic functions including DNA transcription and chromatin modification are overrepresented in the transcriptional signature of BRCA1 mutant cells. Interestingly, many of the upregulated genes are involved in the establishment and/or maintenance of chromatin structure, including demethylases, methyltransferases, histones, acetyltransferases, and several components of the ubiquitin pathway. These observations are consistent with the idea that BRCA1 mutations affect large-scale chromatin unfolding (Ye et al., 2001 ), underscoring its role as an integral component of multiprotein complexes that modulate gene expression (Narod and Foulkes, 2004) .
Second, the distinct transcriptional profile of BRCA1 mut/+ cells may reflect activation of signaling pathways associated with progenitor/basal cells, increased basal differentiation, and decreased luminal differentiation. Previous results suggest that a reduction in BRCA1 leads to a failure of luminal lineage commitment and increased expansion of an uncommitted progenitor EpCAM À population (Liu et al., 2008 observe defects in luminal progenitor differentiation. This difference might reflect the genetic differences between the BRCA1 patient populations in the two studies. Nonetheless, overall these studies reinforce the idea that BRCA1 is a critical regulator of breast epithelial progenitor lineage commitment. All of the BRCA1-mutation carrier samples used in this study harbored frameshift mutations that compromise at a minimum the C-terminal BRCT domain ( Figure S2 ), which could destabilize protein-protein interactions between BRCA1 and its C-terminal binding partners. However, the overall levels of BRCA1 expression were surprisingly not affected. In addition, perturbations in differentiation and increases in Slug expression could be detected without changes in BRCA1 levels, implying that the effects of BRCA1 mutation may be at the level of protein-protein interactions rather than overall BRCA1 expression. Consistent with this notion, reduction of BRCA1 in MCF10A cells by RNA interference impaired differentiation and could be rescued by KRT19  KRT8  CDH1  BMI1  CD44  FN1  FOXC1  SPARC  MMP14  SERPINE  OXTR  CALLA  FGFR1  GATA3  ITGB4  PROM  MUC1  TFF3  CLDN8  CD24  C-MYB   1 CDH3  FN1  KRT14  MMP14  SPARC  SERPINE  THSD1  CD44  KRT17  KRT5  TGFB1  VIM  ID4  IGFBP7  NOTCH3  ITGB4  CLDN7  KRT19  LCN2  PROM1  EpCAM  ERBB3  c- expression of a wild-type or a RAD51 mutant of BRCA1 but not with a BRCA1 C-terminal BRCT domain mutant (Furuta et al., 2005) . Future studies will be necessary to fully dissect the precise domains and mechanism by which BRCA1 regulates breast epithelial differentiation. In addition, further experiments will be needed to determine whether certain mutations in BRCA1 affect differentiation and regulate progenitor cell fate differently than others and whether different mutations alter the propensity for the development of basal-like tumors. The observation that BRCA1 mut/+ epithelial cells express genes involved in melanogenesis and stem cell biology prompted us to examine Slug and its requirement for maintaining progenitor cells and basal differentiation. We found that haploinsufficiency or knockdown of BRCA1 was associated with increased expression and stability of the transcriptional repressor Slug and that Slug regulated the basal epithelial and tumor phenotype. This suggests that perturbations in luminal differentiation due in part to Slug expression is probably responsible for the increased propensity for the development of tumors with basal-like features. Although our results do not address whether Slug is sufficient to induce basal differentiation, Slug is expressed in breast stem/progenitor cells, can promote a basal-like phenotype in the luminal MCF-7 breast cancer cell line, and can increase basal differentiation in the nontumorigenic MCF10A breast line (Sarrio et al., 2008) . Moreover, the fact that Slug is expressed in basal-like breast cancers not associated with BRCA1 mutations (Storci et al., 2008 ) also implies that acquisition of its expression enables basal differentiation.
EXPERIMENTAL PROCEDURES
Detailed methods are described in Supplemental Experimental Procedures.
BRCA1-Mutation Carrier Tissues
All human breast tissue procurement for these experiments was obtained in compliance with the laws and institutional guidelines, as approved by the institutional IRB committee from Beth Israel Deaconess Medical Center (BIDMC) and Tufts University School of Medicine. Disease-free prophylactic mastectomy (n = 31; 12 fresh, 19 formalin-fixed paraffin-embedded) and tumor tissues (n = 19) derived from women carrying a known deleterious BRCA1 heterozygous mutation were obtained with patient consent from the Surgical Pathology files or immediately after prophylactic mastectomy surgery at BIDMC. Tissues in which BRCA1 mutation was confirmed but not known were submitted for sequence/genotyping at Myriad Genetic Laboratories. Non-BRCA1 tumor tissues (n = 20) were obtained from discarded material at Tufts Medical Center and noncancerous breast tissue was obtained from patients undergoing elective reduction mammoplasty at Tufts Medical Center or BIDMC (n = 38; 18 fresh, 24 formalin-fixed paraffin-embedded). BRCA1 mutation status and clinical information are listed in Table S1 . The range of patient ages for fresh BRCA1 +/+ tissue used in this study was 30-54 with a median age of 40; the range of patient ages for fresh BRCA1 mut/+ tissue used in this study was 35-53 with a median age of 44. All disease-free breast tissues were verified by surgical pathologists prior to use in these studies.
Cell Lines and Tissue Culture SUM cell lines were obtained from Dr. Stephen Ethier (Kramanos Institute, MI), and the MCF10A cell lines were purchased from ATCC. MCF10A cells were cultured in DMEM with 10% calf serum. SUM149PT cells were cultured in Ham's F12 with 5% calf serum, insulin (5 mg/mL), and hydrocortisone (1 mg/mL) whereas SUM1315MO2 were in Ham's F12 with 5% calf serum, insulin (5 mg/mL), and EGF (10 ng/mL). All cell lines were grown at 37 C and 5% CO 2 . BRCA1 mut/+ HMECs were immortalized with the catalytic subunit of human telomerase as previously described (Elenbaas et al., 2001) . BHME cells were cultured in MEGM (Lonza) supplemented with bovine pituitary extract (BPE), insulin (5 mg/mL), EGF (10 ng/mL), and hydrocortisone (1 mg/mL).
Lentiviral Constructs and Virus Production
Lentiviral constructs used for gene transduction into human mammary epithelial cells were created with standard cloning techniques into the self-inactivating CS-CG (Miyoshi et al., 1998) . Site-directed mutagenesis was employed to change amino acid residue 175 from R to H. The VSV-G-pseudotyped lentiviral vectors were generated by transient cotransfection of the vector construct with the VSV-G-expressing construct pCMV-VSV-G (Miyoshi et al., 1998) and the packaging construct pCMV DR8.2Dvpr (Miyoshi et al., 1998) , generously provided by Inder Verma, into 293T cells with the FuGENE 6 transfection reagent (Roche). High-titer stocks of the virus were prepared by ultracentrifugation at 100,000 3 g. Lentiviral shRNA constructs targeting Slug (Addgene plasmids 10904 and 10905) were prepared as previously described (Gupta et al., 2005) . Breast tissues were minced and enzymatically digested overnight with a mixture of collagenase and hyaluronidase as previously described (Kuperwasser et al., 2004; Proia and Kuperwasser, 2006 ) and dissociated to a single cell suspension. Immediately after dissociation, cells were resuspended with lentiviruses expressing the genes of interest and injected into cleared and humanized mammary fat pads.
Animals and Surgery
All animal procedures were conducted in accordance with a protocol approved by the Tufts University IACUC committee. A colony of immunocompromised NOD/SCID mice was maintained in house under aseptic sterile conditions. Mice were administered autoclaved food and water ad libitum. Surgeries were performed under sterile conditions, and animals received antibiotics in the drinking water up to 2 weeks after all surgical procedures. Animals were humanized and injected as previously described (Kuperwasser et al., 2004; Proia and Kuperwasser, 2006) .
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections with sodium citrate antigen retrieval, followed by visualization with the ABC Elite peroxidase kit and NovaRed substrate (Vector Labs) for detection of aSMA (1:500, clone asm-1), CK14 (1:500, clone LL002), CK8/18 (1:500, clone DC-10), Vimentin (1:500, clone V9), CK19 (1:500, clone b170) (all, Vector Labs), TFF3 (Abnova, clone 3D9, 1:200), and Slug patient-derived breast epithelial cells were infected with lentiviruses encoding mutant p53, cyclin D1, and K-ras with shSlug or a scrambled sequence (shCntrl) and a quantitative RT-PCR array was performed. Genes differentially expressed >2-fold in both patient samples compared to the scrambled controls are plotted. Error bars are ±SEM and p values were calculated by two-tailed t test. See also Figure S7 and Table S6 .
Center. IHC results were semiquantitatively analyzed (see Supplemental Experimental Procedures for details).
Mammospheres and Adherent Colony Forming Assays
Viable cells dissociated from organoids derived from BRCA1 +/+ (n = 4) and BRCA1 +/À (n = 4) patients were plated at 35,000 cells per well in 6-well plates for adherent colony growth in MEGM media (Lonza) or at 20,000 cells per ml in 6-well ultralow attachment plates (Corning) in MEGM media minus the addition of bovine pituitary extract for mammosphere growth. Colonies and mammospheres were allowed to form for 8 days after which nonadherent suspension colonies from adherent culture and mammospheres from nonadherent culture were collected for analysis. Mammospheres collected from nonadherent culture and suspension colonies collected from adherent culture were cytospun onto glass slides and fixed in methanol for immunofluorescence analysis. Quantification of mammosphere and suspension colony numbers was accomplished with a Multisizer 3 COULTER COUNTER (Beckman-Coulter).
Immunomagnetic Bead Sorting Epithelial organoids from BRCA1
+/+ and BRCA1 mut/+ patients were dissociated to a single cell suspension and sorted with CELLection pan-mouse IgG magnetic beads according to the manufacturers' instructions and as described previously (Allinen et al., 2004 ) (Dynal, Invitrogen) conjugated to a CD10 antibody (DAKO). CD10 + cells were released from the beads by DNase treatment per the manufacturer's instructions. Cells that did not bind to the CD10-immunobeads were further sorted with magnetic beads conjugated to an EpCAM antibody (Abcam).
Flow Cytometry and FACS
Uncultured cells from BRCA1 +/+ (n = 10) or BRCA1 mut/+ (n = 7) organoid preparations were dissociated to a single-cell suspension as described above and filtered through a 20 mm nylon mesh (Millipore). Endothelial, lymphocytic, monocytic, and fibroblastic lineages were depleted with antibodies to CD31, CD34, and CD45 (all Thermo/LabVision) and Fibroblast Specific Protein/IB10 (Sigma) and a cocktail of Pan-mouse IgG and IgM Dynabeads (Dynal, Invitrogen) according to the manufacturer's instructions and as described previously (Villadsen et al., 2007) and in Supplemental Experimental Procedures. Nonconfluent cultures of SUM149, SUM1315, and immortalized HMECs cells were trypsinized into single-cell suspension, counted, washed with PBS, and stained with antibodies specific for human cell CD24 (PE) and CD44 (APC) (BD Biosciences). Antibody-bound cells were washed and resuspended at 1 3 10 6 cells/ml in FB and run on a FACSCalibur flow cytometer (BD Biosciences) or sorted on a BD Influx FACS sorter (BD Biosciences). Flow cytometry data was analyzed with the Flowjo software package (TreeStar). 
Microarray and RT-PCR Analysis
ACCESSION NUMBERS
The accession number for the microarray data is GSE25835.
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